New drug combo shows promise in early trial for advanced melanoma
NCT ID NCT03769155
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether adding an experimental drug called VX15/2503 to standard immunotherapies (ipilimumab or nivolumab) can help treat stage IIIB-D melanoma that can be removed by surgery. About 41 participants will receive the drug combination before surgery to see how it affects immune cells in the tumor. The goal is to find better ways to shrink or control the cancer before surgical removal.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VX15/2503 (pepinemab) combined with ipilimumab or nivolumab
- What this could lead to
- If successful, this could point toward a more effective treatment approach for advanced melanoma that can be surgically removed.
- What could go wrong
- This is an early phase 1 trial with only 41 participants, so results are preliminary and may not lead to a standard treatment. Side effects from the drug combination are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat cancers
- Milder chemo before TIL therapy shows promise for tough-to-treat melanoma
- Experimental triple therapy for advanced cancers shows early promise but trial halted
- Melanoma survivors: new study tracks immunotherapy side effects
- Patient's own immune cells plus drug tested against tough melanoma
- Engineered virus takes on Hard-to-Treat melanoma